Pulmonary effects and disposition of luteolin and Artemisia afra extracts in isolated perfused lungs

Sizwe Joel Mjiqiza, James Abraham Syce, Kenechukwu Chibuzo Obikeze

Abstract

**Ethnopharmacological relevance:** Artemisia afra (Asteraceae) is a traditional medicinal plant frequently used in steam inhalation form to treat respiratory conditions.

**Aim of the study:** Quantify luteolin content in Artemisia afra dried crude and aqueous extract. Evaluate the pulmonary effects of Artemisia afra steam inhalation, nebulized Artemisia afra extract and luteolin in isolated perfused lungs (IPL). Evaluate the pulmonary disposition of intravenously administered luteolin.

**Materials and methods:** HPLC was used to quantify luteolin in Artemisia afra extracts. A modified version of the IPL was used to determine the effects of Artemisia afra steam inhalation, nebulized luteolin, and nebulized aqueous leaf extract on lung function, as well as the pulmonary disposition of IV luteolin.

**Results:** Artemisia afra extract contained significantly higher luteolin levels than the crude dried leaves. Inhaled Artemisia afra steam, and nebulized luteolin, and Artemisia afra extract and IV luteolin produced significant dose-dependent improvements in lung function, with nebulized Artemisia afra producing the greatest improvements. Nebulisation with Artemisia afra extract yielded higher quantities of luteolin than luteolin nebulisation.

**Conclusion:** Results verify the traditional use of inhalation of Artemisia afra steam, although nebulized luteolin and aqueous extract are better alternatives. Luteolin significantly contributes to the broncho-dilatory effects of Artemisia afra.

1. **Introduction**

Traditional medicines remain a source of viable alternatives for affordable healthcare especially in developing countries (Mayosi et al., 2009). In South Africa an estimated 70% of the population depend on traditional medicines largely comprising of plants such as Artemisia afra Jacq. ex Willd (Asteraceae) for treatment of a wide variety of diseases (Mander et al., 1997).

Artemisia afra, a multi-stemmed perennial shrub with greyish-green feathery leaves, enjoys widespread use in traditional medicines in South Africa for the treatment of a
wide variety of illnesses. The most prevalent use is for the treatment of respiratory disorders such as coughs, colds, bronchitis, blocked sinuses and tight-chest or asthma in the form of a steam inhalation of the leaves (Roberts, 1990; Iwu, 1993; Van Wyk and Gerike, 2000a). Extracts of the plant leaves have been shown to exhibit various pharmacological effects including relaxation of respiratory smooth muscles contracted by various known broncho-constrictors, but the bronchodilatory effect of the plant in the form that it is used in traditional medicine (steam inhalation) is yet to be assessed in intact lungs and the exact plant chemical constituents responsible for this activity is still unknown (Roberts, 1990; Van Wyk and Gerike, 2000b; Waithaka, 2004).

Flavonoids, found in appreciable quantities in Artemisia afra, have been suggested to be responsible for the bronchodilatory effect of the extracts (Harris, 2002). Artemisia afra contains several flavonoids, including apigenin, chrysoeriol, tamarixetin, acacetin, genkwanin and kaempferol (Kraft et al., 2003; Waithaka, 2004; Avula et al., 2009) with the aqueous extract containing greater quantities of luteolin and quercetin than the other flavonoids (Muganga, 2004; Waithaka, 2004; Mukinda et al., 2010). These 2 flavonoids are also easily extractable from the plant, stable under various processing conditions, and selectively quantifiable using HPLC, thus making them ideal markers when evaluating Artemisia afra extracts, (Markam, 1982; Harborne and Williams, 2000; Waithaka, 2004; Springfield et al., 2005, Mukinda et al., 2010). Luteolin however with its greater quantities (Muganga, 2004; Waithaka, 2004), anti-inflammatory, antispasmodic (Yamazaki et al., 2002), and muscle relaxant activity (Sanchez de Rojas et al., 1995; Harris, 2002; Das et al., 2003) is the ideal candidate for a marker compound.

Although the pharmacokinetics and bioavailability of luteolin has been studied using various models, the pharmacokinetics following pulmonary administration is yet to be carried out (Shimoi et al., 1998; Spencer et al., 1999; Scalbert and Williamson, 2000; Wang et al., 2003; Muganga, 2004; Lui et al., 2005, Mukinda et al., 2010). To study the pharmacokinetics of luteolin in the lungs as well as the effects of Artemisia afra on lung parameters, the isolated perfused lung (IPL) model was chosen. It provides a suitable model for measuring the delivery and pharmacokinetics of Artemisia afra in the lungs as well as the effect on pulmonary parameters such as lung resistance and compliance whilst minimizing the influence of the nervous system, hormones, and chemical mediators circulating in plasma. It also allows for the simultaneous measurement of respiratory mechanics such as tidal volume, lung compliance, and resistance and can easily be adapted for administration via inhalation, instillation, bolus injection or continuous perfusion (Uhlig and Wollin, 1994; Uhlig and Taylor, 1998; Mjiqiza, 2006).

In this study, the isolated perfused lung (IPL) model was used to evaluate the pulmonary effects of the traditionally-prepared Artemisia afra steam inhalation, nebulized Artemisia afra aqueous extract and luteolin solutions. Luteolin content in dried crude Artemisia afra leaves and an aqueous extract of Artemisia afra leaves were quantified using HPLC and the pulmonary disposition and effect of intravenously administered luteolin in IPL determined.
2. Materials and methods

2.1 Chemicals and reagents

Sodium chloride, potassium chloride, calcium chloride 2-hydrate, potassium dihydrogen phosphate, magnesium chloride 6-hydrate, sodium hydrogen carbonate and glucose (all of analytical grade; Holpro Analytics Pty Ltd., Johannesburg, South Africa); bovine serum albumin (Fraction V), luteolin (97%) and dimethyl sulfoxide (all Sigma-Aldrich, South Africa, Vorna Valley, South Africa); heparin sodium (Fresenius Kabi (Pty) Ltd., Cape Town, South Africa); sodium pentobarbitone (Kyron Laboratories (Pty) Ltd., Johannesburg, South Africa); carbon dioxide, helium and nitrogen (all from Afr ox Ltd, Epping, South Africa); concentrated hydrochloric acid, methanol, and acetone (all analar grade; KIMIX Chemicals & laboratory suppliers, USA); acetonitrile (HPLC grade, ACS specifications, Allied Signal Inc.); and formaldehyde and ethyl acetate (AR Saarchem Merck Chemicals (PTY) LTD), were used in the preparation of the plant materials, the assay of the plant materials, lung and perfusate samples and the isolated perfused lung experiments.

2.2 Preparation of Artemisia afra extracts

Artemisia afra was obtained from Montague museum (Montague, South Africa) and identified by Riaan Cedras at the herbarium at UWC (voucher specimen 6735). Fresh leaves were dried at 30°C for 72 h in a well-ventilated oven until a constant weight, and ground to a fine powder. Aqueous extraction of 100 g of dried ground plant leaves with 1 L of boiling distilled water for 30 min was carried out, and the resultant infusion filtered, and freeze-dried to produce a dry, flaky brownish extract. The resultant aqueous extract was stored in a desiccator in sealed amber bottles until further use.

2.3 HPLC assay for the determination of luteolin levels

The HPLC assays used in the study were all validated for separation and specificity, inter- and intra-day variability, recovery, linearity and lowest limit of detection. HPLC assays of un-hydrolyzed and hydrolyzed dried leaves and aqueous extract were carried out to quantify luteolin (aglycone and glycoside) levels in Artemisia afra. To prepare un-hydrolyzed Artemisia afra for HPLC assay, 25 mg of the aqueous extract and 100 mg of the dried leaves were dissolved in 300 ml and 1 ml of distilled water respectively. The internal standard, Morin (100 ml) was added to each sample, the contents thoroughly vortex-mixed for 1 min, and thereafter extracted with 5 ml ethyl-acetate. To produce hydrolyzed samples 4 ml of 2N HCl was added to the vortexed mixture and heated in a water-bath at 80°C for 40 min, cooled to room temperature, and extracted with 5 ml of ethyl-acetate. The ethyl-acetate extracts were evaporated to dryness under a gentle stream of nitrogen gas, the residue re-dissolved into 500 ml of the mobile phase and 100 ml of the solution run on a Beckman System Gold HPLC system (32-Karat™ software package) consisting of a programmable binary gradient pump (Beckman Gold Module 126 series), an auto sampler (Beckman Gold Module 507 series) with a diode array detector (Beckman Gold Module 168 series) (all Beckman, USA) and a Luna® C-18 reverse phase column (Phenomenex, USA). Eluting solvent was a mixture of acetonitrile and phosphate buffer (100 mM, pH 2) (3:7) pumped isocratically at a flow rate of 1 ml/min. The luteolin peaks were detected at the wavelength of 349 nm.
2.4. The isolated perfused lung system

Male Wistar rats (300–400 g) obtained from the University of Cape Town (UCT) and the Medical Research Council (MRC), South Africa were used in this study. The animals were kept on a 12-h light/12-h darkness cycle in a well-ventilated animal room and allowed free access to food and water. All animal experiments were conducted in accordance with the internationally accepted principles for laboratory animal use and care, and the protocol as approved by the ethics committees of the MRC and University of the Western Cape (UWC).

A modified version of the isolated perfused lung (IPL) system as described by Uhlig and Taylor (1998) was used to determine the effects of *Artemisia afra* steam inhalation, nebulized luteolin, and nebulized aqueous leaf extract on lung function, as well as the pulmonary disposition of intravenous administered luteolin. In this system, the jacketed organ chamber was fitted with a pneumotachometer to measure airflow rate, while the lungs were perfused via a pulmonary arterial cannula connected to a peristaltic pump, and discharged via a pulmonary venous cannula. A bubble trap in the pulmonary arterial cannula allowed for the bolus administration of drugs and also contained a pressure transducer used for the continuous measurement of pulmonary arterial pressure (PAP). The lung chamber was also linked to a chamber pressure transducer for measuring trans-pulmonary pressure (chamber pressure). Ventilation of the lung was achieved by a ventilation control module (VCM) connected to the trachea via a tube containing a change-over valve that allowed for the switch of ventilation between negative and positive pressure ventilation. The respiratory rate and the level of the end-expiratory and end-aspiratory pressures were controlled by the VCM settings while the frequency of deep breaths (“sighs”) was adjusted through the timer counter module (TCM).

Male Wistar rats (300–400 g) were anaesthetized with sodium pentobarbitone (100 mg/kg; IP), tracheotomised with a cannula and ventilation at positive pressures of about 10 cm H$_2$O and 80 breaths/min started. The animal was then exsanguinated, and the upper abdomen and thorax dissected to expose the lungs. The right ventricle was cannulated with an arterial cannula, while the left atrium was cannulated with a venous cannula. Perfusion with the perfusion fluid was then initiated at 5 ml/min while the lungs were dissected free of the animal and placed in the artificial thorax chamber (Uhlig and Wollin, 1994). Positive pressure ventilation was then stopped and lungs switched to negative pressure ventilation with the pressure in the chamber fluctuating between an end-inspiratory pressure of $-10$ to $-16$ cm H$_2$O and end-expiratory pressure of $-2$ cm H$_2$O. Perfusion flow rate was also increased to 25 ml/min and a pneumotachometer connected to the external input module (EIM) via a differential pressure transducer (Validyne®, model DP45-24) and an amplifier (model SP 2040D) inserted into the organ chamber to measure the airflow rate. Perfusion fluid (Krebs-Henseleit buffer containing calcium chloride 2.5 mM, Magnesium sulfate 1.2 mM, sodium chloride 118
mM, potassium chloride 4.7 mM, potassium dihydrogen phosphate 1.2 mM, 2% bovine serum albumin (BSA), and 0.1% glucose; pH 7.3–7.4) was pumped through the lung vasculature using single pass perfusion for 5 min to clear the organ debris before changing to recirculation mode for the rest of the experiment to mimic the normal body circulation. Lungs were allowed to equilibrate and stabilize for 20 min before treatment with test compounds. At the end of each experiment, the lungs were assessed for edema formation, and separated from the trachea and the heart before being weighed on an electronic balance. During experiments tidal volume, mean pulmonary pressure, airflow rate and trans-pulmonary pressure were continuously monitored via the PLUGSYS™ system on a computer. Lung resistance (LR) and compliance (LC) values were determined automatically from airflow rates and pulmonary pressure readings by the PULMODYN™ computer software. In order to determine the viability of the model, lungs were perfused with perfusate for 2 h and were found to be stable with the following values for pulmonary parameters at the start and end of perfusion: tidal volume (4.3670.16–3.4870.91); lung resistance (0.5270.07–0.6170.05) and lung compliance (0.6470.57–0.5870.17).

2.5 Effects of traditionally prepared Artemisia afra steam inhalation on lung function
To determine the effects of traditionally prepared Artemisia afra steam inhalation on lung function, dried leaves of Artemisia afra were boiled for 5 min and the resulting steam introduced into the IPL system via 3 cooling and condensation chambers with compressed air used to drive the steam of the resultant vapor in the direction of the organ chamber. The lungs were allowed to inhale the steam for 3 min under negative ventilation and thereafter lung function monitored for 30 min. A second outlet of the steam-feeder was immersed in 1 ml of distilled water during steam inhalation to trap aerosolized compounds and the sample subjected to HPLC analysis to identify and quantify the amount of luteolin aerosolised during the steam inhalation period. Control lungs received 3 min of inhaled steam from 100 ml saline, while test lungs received steam from either 10 mg/ml (1 g in 100 ml saline) or 50 mg/ml (5 g in 100 ml saline) Artemisia afra.

2.6 Effects of nebulized luteolin and aqueous Artemisia afra extract on lung function
To determine the effects of nebulized luteolin and the aqueous extract of Artemisia afra on lung function, a jet nebulizer used to generate the aerosol was linked via a thin silicone tube to the thorax chamber. The lungs were nebulized for 3 min under negative ventilation either with 4 ml of saline (control), 4 ml saline containing 250 mg luteolin per 1 ml of saline or 4 ml saline containing 100 mg Artemisia afra aqueous extract per 1 ml of saline (equivalent to 250 mg luteolin per ml of saline). Lung function was monitored thereafter for 30 min. During nebulisation, a second outlet of the nebulizer feeder was immersed in 1 ml of distilled water to trap aerosolized compounds, and the sample analyzed with HPLC to identify and quantify the amount of luteolin trapped during the nebulization period.
2.7 Disposition and effect of IV administered luteolin in IPL

To determine the effect and disposition of luteolin in the lungs, the following procedure was followed. Lungs were perfused with a perfusion solution containing either 2 mg/ml or 10 mg/ml of luteolin for 90 min. During luteolin perfusion, 1 ml samples of perfusate were collected at 3, 5, 10, 15, 30, 45, 60, 75 and 90 min and stored at 2°C for later analysis. Perfusate samples were then divided into 2 x 500 ml samples to assay for luteolin in hydrolyzed and un-hydrolyzed samples. Each 500 ml perfusate was spiked with 10 mg morin (internal standard), vortex-mixed and then 1 ml methanol added to precipitate proteins. Un-hydrolyzed samples were then directly extracted with 5 ml of ethyl-acetate, while for hydrolyzed samples, 2ml of 2N HCL was added to each sample, heated in a water bath at 80°C for 40 min, cooled to room temperature, and extracted with 5 ml of ethyl acetate. Ethyl acetate extracts were evaporated to dryness under a stream of nitrogen gas, the residue re-dissolved into 500 ml of HPLC mobile phase, and 100 ml of the solution injected into HPLC column for analysis.

2.8 Data analysis

To determine the changes in lung mechanics after treatment with the different plant compounds, the following parameters were observed: tidal volume (TV), lung compliance (LC) and resistance (LR) (calculated using the PULMODYN Software). Mean values (n \( \frac{1}{4} 5 \)) at each specified time interval was calculated and two-way ANOVA analysis followed by the Bonferroni post test or t-test analysis used to determine the statistical significance. To determine the levels of luteolin in the plant extracts and the effluent perfusate, luteolin and morin peak heights were obtained from the HPLC 32-Karat software package generated data, and the luteolin to morin peak height ratios calculated using Excel. The concentration vs. ratios data were then subjected to linear regression analysis, and used for construction of the standard curve and luteolin concentrations determined from the same standard curve using Graphpads Prism software.

3. Results

3.1 Identification and quantification of luteolin in the plant material

The developed HPLC assay was fairly robust, linear over the concentration range of 5–30 mg of luteolin/ml solution with a correlation coefficient \( r^2 \) of 0.9916. The assay had high assay reproducibility (i.e. CV below 3%), was quite sensitive with a LLQ of 70 ng on column, and therefore deemed suitable for the study. Hydrolyzed and un-hydrolyzed forms of the aqueous extract and dried leaves of Artemisia afra were analyzed by HPLC assay. Each extract produced distinct peaks for luteolin with a retention time of 14.4370.298 min, which were easily quantifiable (Fig. 1 and Table 1). Additional peaks with much shorter retention times than luteolin and morin (internal standard) were evident in the chromatograms, with the peaks from the solutions of the hydrolyzed extract being more prominent than that of the hydrolyzed leaves (Table 1).
3.2 Effect of *Artemisia afra* steam inhalation, nebulized freeze-dried *Artemisia afra* aqueous extract and nebulized luteolin on lung mechanics

3.2.1 Effect on tidal volume
Steam inhalation from 1 g and 5 g quantities (10 mg/ml and 50 mg/ml) of the dry leaves of *Artemisia afra* boiled in 100ml of normal saline led to no statistically significant initial changes in tidal volume (TV) post exposure—3.6% (from 4.1970.129 ml to 4.3470.140 ml) and 7.6% (from 4.2270.120 ml to 4.5470.088ml) respectively (Fig. 2).

This was however followed by a decrease at a steady rate of 0.01470.0042 ml/min for 10 mg/ml, while the increase in TV from the 50 mg/ml dose was sustained for 16 min before decreasing at a steady rate similar to that of the 10 mg/ml and saline group of lungs. Nebulizing the lungs with luteolin (250 ug/ml) led to a statistically significant (11%) increase in TV (from 3.8670.078 ml to 4.2570.189 ml) which was sustained for the duration of the post-nebulization period (Fig. 2). Nebulizing with *Artemisia afra* aqueous extract also led to a statistically significant (18%) increase in TV, which was greater than that produced by all other drugs, and sustained throughout the monitoring period (Fig. 2).
Perfusion with luteolin (2 mg/ml and 10 mg/ml) led to no statistically significant initial changes in TV (5.6% and 13.7% decreases respectively). However, post-perfusion rate of decrease was statistically significantly less than the pre-treatment rate for both doses indicating that luteolin administered into the perfusion media stabilized the tidal volume (Fig. 2).

3.2.2. **Effect on lung compliance**

Steam inhalation of *Artemisia afra* leaves led to statistically significant dose-dependent increases in lung compliance (LC), with the 10 mg/ml and 50 mg/ml doses increasing LC by 3.4% (from 0.6270.022 ml/cm H$_2$O to 0.6470.019 ml/cm H$_2$O) and 11.8% (from 0.5970.026 ml/cm H$_2$O to 0.6670.027 ml/cm H$_2$O) respectively (Fig. 3). Increase in LC with the lower dose was sustained for only 20 min, while the increase from the higher dose was sustained throughout the experimental period.

Nebulizing the lungs with luteolin (250 ug/ml) led to a statistically significant 36.4% increase in LC (from 0.6570.012 ml/cm H$_2$O to 0.8870.019 ml/cm H$_2$O) (Fig. 3). This improvement was sustained for the entire post nebulization monitoring period. When the lungs were however nebulized with *Artemisia afra* extract equivalent to 250 ug/ml of luteolin, LC improved by 43.4% (from 0.7070.029 ml/cm H$_2$O to 1.0070.043 ml/cm H$_2$O), and only exhibited a slight decline during the monitoring period (Fig. 3). Intravenous perfusion with luteolin (2 mg/ml) produced an initial non-statistically significant (1%) change in LC (from 0.5170.039 ml/cm H$_2$O to 0.5170.047 ml/cm H$_2$O) (Fig. 3). Lung compliance however increased at a steady rate (0.005587 0.00289 ml/cm H$_2$O/min) throughout the posttreatment period leading to a peak value (1.0270.093 ml/cm H$_2$O) representing a statistically significant 98.5% increase. The higher luteolin (10 mg/ml) dose also produced an initial non-statistically significant (1.9%) change in LC (from 0.5470.034 ml/cm H$_2$O to 0.5570.039 ml/cm H$_2$O), also followed by a steady rate (0.0072170.00113 ml/cm H$_2$O/min) increase over the post treatment period to a statistically significant higher final value of 1.1770.028 ml/cm H$_2$O (Fig. 3).

3.2.3. **Effect on lung resistance**

Steam inhalation with and 50 mg/ml *Artemisia afra* leaves extract led to an initial statistically significant decreases in lung resistance (LR) (9.7% and 11% respectively). This was however followed by an increases at steady rates similar to and slightly higher than the pre-inhalation rate for the 10 mg/ml (0.0031170.00148 cm H$_2$O s/ml/min) and 50mg/ml (0.0058470.00096 cm H$_2$O s/ml/min) doses respectively (Fig. 4).
Nebulizing the lungs with luteolin (250 ug/ml) led to an initial statistically significant 19.7% decrease in LR (from 0.6670.014 cm H2O s/ml to 0.5370.014 cm H2O s/ml), followed by an increase at a steady rate (0.0057470.0009 cm H2O.s/ml/min) similar to the post-nebulization rate of increase in the saline group. *Artemisia afra* extract nebulisation on the other hand also led to a statistically significant though smaller decrease in LR (by 8.5%; from 0.6370.013 cm H2O s/ml to 0.5770.038 cm H2O s/ml). This decrease unlike that produced by luteolin was sustained throughout the post-nebulization period (Fig. 4).
Intravenous perfusion with luteolin (2 mg/ml) led to an initial non-statistically significant change in LR (from 0.5670.065 cm H₂O s/ml to 0.5570.065 cm H₂O s/ml), with a further decrease (to 0.4170.077 cm H₂O s/ml) occurring after 10 min post-perfusion followed by an increase (to 0.4970.044 cm H₂O s/ml) after 25 min, and then a gradual decline followed by a slight increase towards the end of the monitoring period to levels which were statistically significantly lower than the pre-treatment levels. The higher luteolin dose (10 mg/ml) induced an initial statistically significant increase in LR (from 0.4170.052 cm H₂O s/ml to 0.5770.063 cm H₂O s/ml), followed by a brief, sharp drop to 0.406070.07716 cm H₂O s/ml after 10 min, then a subsequent steady increase in levels over 35 min, and finally a gradual decrease to values that remained significantly higher than the pre-treatment LR levels at the end of the post treatment period (Fig. 4).

3.3. The disposition profile of intravenously administered luteolin in the IPL

Analysis of luteolin levels in lung perfusion medium indicated that pre-perfusion the 2 mg/ml luteolin perfusate contained 1.9670.0143 mg/ml free (un-hydrolyzed luteolin), while a comparable 1.9870.0074 mg/ml was obtained after acid hydrolysis. For the higher dose (10 mg/ml), free luteolin was 9.8670.0933 mg/ml and aglycone luteolin level was 9.8770.0098 mg/ml, confirming that no alteration in luteolin levels occurred in the albumin containing perfusion medium.

Levels of free luteolin in the lung perfusate first increased slightly, then decreased at a rapid rate (0.1870.002086 mg/ml/ min) for about 30 min, followed by a slower rate of decrease (0.4970.003674 mg/ml/min) to the end of the perfusion period. The first order rate constant and half-life for the terminal phase were 8.73 x 10⁻³ min⁻¹ and 79.381 min, respectively. For the higher luteolin dose (10 mg/ml), the free luteolin perfusate levels first increased to 7.4070.01647 mg/ml, decreased at a steady rate (0.5970.0019 mg/ml/min) for 5 min before increasing steadily (0.4270.01667 mg/ml/min) until the end of the perfusion period. The first order rate constant and half-life for the terminal phase were 2.501 x 10⁻⁴ min⁻¹ and 2770.89 min, respectively (Table 2).

4. Discussion

Traditionally prepared Artemisia afra aqueous extract contained higher content of luteolin than the freeze-dried extract, with approximately 50% of luteolin in acid-hydrolyzable, presumably glycoside form. Higher concentrations of luteolin have been extracted from the plant and the lower concentrations isolated here is most likely due to the nature of the solvent used in the process (Muganga, 2004). The results confirmed the presence of quantifiable amounts luteolin in Artemisia afra extracts as previously reported by other researchers (Muganga, 2004; Waithaka, 2004), indicating the possibility that luteolin may be implicated in any effect the extracts have on the lungs.
For this study the IPL was a particularly useful and novel tool to evaluate both the pulmonary effect of, and the pulmonary availability of an active constituent (luteolin) in *Artemisia afra*, as it would be administered traditionally, i.e. in steam inhalation form. Moreover changes in the pulmonary parameters such as TV, LR and LC are particularly appropriate and sensitive indicators of anti-asthmatic activity. Tidal volume is the volume of gas inspired or expired during each respiratory cycle. It usually decreases during bronchoconstriction and increases during bronchodilation, and is often affected during pulmonary disorders such as asthma and COPD (Ruppel, 2004). Compliance is the volume change per unit of pressure change for lungs and is measured in millimeters per centimeter of water (ml/cm H$_2$O) (Ruppel, 2004). CL is an index of functional stiffness of the lung and reflects changes to small airways, thus making compliance a useful test to indicate changes in periphery of the lung (Drazen, 1984). It is normally decreased in pulmonary edema or congestion, atelectasis, pneumonia and restrictive diseases such as pulmonary fibrosis and asthma. Known bronchodilators

For this study the IPL was a particularly useful and novel tool to evaluate both the pulmonary effect of, and the pulmonary availability of an active constituent (luteolin) in *Artemisia afra*, as it would be administered traditionally, i.e. in steam inhalation form. Moreover changes in the pulmonary parameters such as TV, LR and LC are particularly appropriate and sensitive indicators of anti-asthmatic activity. Tidal volume is the volume of gas inspired or expired during each respiratory cycle. It usually decreases during bronchoconstriction and increases during bronchodilation, and is often affected during pulmonary disorders such as asthma and COPD (Ruppel, 2004). Compliance is the volume change per unit of pressure change for lungs and is measured in millimeters per centimeter of water (ml/cm H$_2$O) (Ruppel, 2004). CL is an index of functional stiffness of the lung and reflects changes to small airways, thus making compliance a useful test to indicate changes in periphery of the lung (Drazen, 1984). It is normally decreased in pulmonary edema or congestion, atelectasis, pneumonia and restrictive diseases such as pulmonary fibrosis and asthma. Known bronchodilators

Table 2

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Free luteolin (μg/ml)</th>
<th>Conjugated luteolin (μg/ml)</th>
<th>Total luteolin (μg/ml)</th>
<th>Free luteolin (μg/ml)</th>
<th>Conjugated luteolin (μg/ml)</th>
<th>Total luteolin (μg/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(μg/ml)</td>
<td>(μg/ml)</td>
<td>(μg/ml)</td>
<td>(μg/ml)</td>
<td>(μg/ml)</td>
<td>(μg/ml)</td>
</tr>
<tr>
<td>0</td>
<td>0.00 ± 0.000</td>
<td>0.00 ± 0.000</td>
<td>0.00 ± 0.000</td>
<td>0.00 ± 0.000</td>
<td>0.00 ± 0.000</td>
<td>0.00 ± 0.000</td>
</tr>
<tr>
<td>3</td>
<td>1.10 ± 0.146</td>
<td>0.27 ± 0.196</td>
<td>1.37 ± 0.372</td>
<td>1.28 ± 0.269</td>
<td>0.98 ± 0.080</td>
<td>2.26 ± 0.349</td>
</tr>
<tr>
<td>5</td>
<td>1.18 ± 0.064</td>
<td>0.46 ± 0.016</td>
<td>1.65 ± 0.042</td>
<td>1.74 ± 0.167</td>
<td>1.08 ± 0.269</td>
<td>2.82 ± 0.116</td>
</tr>
<tr>
<td>10</td>
<td>0.91 ± 0.132</td>
<td>0.66 ± 0.161</td>
<td>1.57 ± 0.263</td>
<td>7.23 ± 0.165</td>
<td>1.00 ± 0.463</td>
<td>8.22 ± 0.271</td>
</tr>
<tr>
<td>15</td>
<td>0.88 ± 0.091</td>
<td>0.43 ± 0.138</td>
<td>1.31 ± 0.118</td>
<td>6.66 ± 0.224</td>
<td>1.01 ± 0.458</td>
<td>7.67 ± 0.173</td>
</tr>
<tr>
<td>30</td>
<td>0.70 ± 0.051</td>
<td>0.28 ± 0.113</td>
<td>0.98 ± 0.080</td>
<td>6.81 ± 0.129</td>
<td>1.01 ± 0.377</td>
<td>7.82 ± 0.268</td>
</tr>
<tr>
<td>45</td>
<td>0.65 ± 0.055</td>
<td>0.33 ± 0.105</td>
<td>0.99 ± 0.069</td>
<td>6.66 ± 0.327</td>
<td>1.09 ± 0.524</td>
<td>7.76 ± 0.264</td>
</tr>
<tr>
<td>60</td>
<td>0.57 ± 0.032</td>
<td>0.31 ± 0.112</td>
<td>0.88 ± 0.082</td>
<td>6.64 ± 0.263</td>
<td>0.99 ± 0.350</td>
<td>7.63 ± 0.264</td>
</tr>
<tr>
<td>75</td>
<td>0.58 ± 0.042</td>
<td>0.20 ± 0.078</td>
<td>0.78 ± 0.078</td>
<td>6.68 ± 0.220</td>
<td>0.85 ± 0.474</td>
<td>7.53 ± 0.404</td>
</tr>
<tr>
<td>90</td>
<td>0.22 ± 0.021</td>
<td>0.20 ± 0.021</td>
<td>0.78 ± 0.278</td>
<td>7.23 ± 0.189</td>
<td>0.58 ± 0.460</td>
<td>8.21 ± 0.346</td>
</tr>
</tbody>
</table>
usually increase the lung compliance (Ruppel, 2004). Finally, airway resistance (RL) is defined as the pressure difference required for a unit flow change and is usually measured in centimeters of water per milliliter per second. It is the measurement of clinical and physiological interest, and is useful for evaluating the respiratory effects of bronchodilatory or bronchoconstrictive drugs. Increased resistance is usually due to narrowing and collapse of airways and clinically related to an assortment of respiratory diseases such as asthma and bronchitis (Lausted and Johnson, 1999; Ruppel, 2004).

Steam inhalation of Artemisia afra induced dose-dependent increases in TV and LC, while leading to decreases in LR. These effects were similar to those obtained with known bronchodilators suggesting that the plant contained compounds with bronchodilatory activity (Svens and Rvrfeldt, 2001). Since luteolin a flavonoid found in Artemisia afra and previously associated with bronchodilatory activities (Das et al., 2003) was found in significant quantities in the extract, it probably played a role in the observed effects of the steam inhalation. Flavonoids have been reported to trigger the release of pulmonary surfactants which in turn reduce the surface tension in the lung tissues, thus reducing airway resistance, while also increasing the elasticity of the lung and hence LC (Niemeier, 1984). Lung compliance was increased in particular possibly via a variety of factors, including increased lung elasticity, smooth muscle relaxation or improved activity of the pulmonary surfactant (Niemeier, 1984). Improved activity of the pulmonary surfactant due to other constituents of the extract may in particular explain the better effect obtained with the extract than with luteolin. However HPLC analysis of the post-lung condensate from the extract did not detect luteolin. This suggests that either luteolin levels were below the limit of detection or that the bronchodilator effects were due to other compounds such as volatile oils like thujone (Roberts, 1990).

Nebulized luteolin also exhibited a bronchodilatory effect, with dose-dependent improvements in lung function (increased TV, LC and decreased LR) greater than those obtained with the steam inhalation Artemisia afra. This ordinarily would have suggested that luteolin was responsible for the bronchodilatory effects of the plant, except that the nebulized Artemisia afra extract produced even greater improvements in lung function. Nebulized Artemisia afra also sustained the improved lung function better than Artemisia afra steam inhalation or nebulized luteolin despite containing luteolin equivalent in dose to the nebulized luteolin dose. The improvement in lung function with nebulized luteolin indicate that luteolin does play a role in Artemisia afra effect, but improved effect with the nebulized extract suggests the presence of either other active constituents (possibly flavonoids such as quercetin) or complimentary compounds in the plant. There is also the possibility of improved bioavailability of luteolin from the plant extract possibly due to surfactant effect from other contained flavonoids. Higher luteolin yields in post-lung condensate from nebulized plant extract than from luteolin correlates with studies showing a better release and greater bioavailability of luteolin when contained in plant material than its aglycone form suggesting that the improved efficacy was due to the improved
bioavailability of the extract (Markam, 1982; Muganga, 2004). Once more despite the evidence of the effect of luteolin on lung function, luteolin was not detected in the perfusate after the inhalation of the nebulized luteolin or *Artemisia afra* aqueous extract solutions. It may be that luteolin levels in the perfusate were below the lower limit of detection of the HPLC assay used in this study, or that the compound had a poor disposition in the lungs or was rapidly metabolized amongst other reasons (Tronde, 2002).

Luteolin was administered IV to study its disposition profile in the lungs at levels that produced comparably changes to lung dynamics as inhalation and nebulisation. Intravenously administered luteolin improved lung function similar to the effects obtained with steam inhalation and nebulisation, further confirming its bronchodilatory effect. A direct correlation between an increase in LC and a decrease in perfusate luteolin levels (indicative of luteolin uptake and/or metabolism) strongly suggests that the improved LC was due to luteolin activity. In fact, luteolin seems to particularly increase the lung compliance, an effect that might be caused by a variety of factors, including increased lung elasticity, smooth muscle relaxation or improved activity of the pulmonary surfactant (Niemeier, 1984). Further studies comparing the luteolin perfusate levels and its lung effects must however, be done before one can truly confirm such hypothesis. Nevertheless, this study strongly suggests that luteolin could be a worthy marker to monitor, establish and quantitate the pulmonary effects of *Artemisia afra*.

Nebulization produced better and more sustainable pulmonary effects than steam inhalation. There may be a variety of reasons for this, including that nebulization provided better deposition of plant actives in the lung than the steam inhalation. The administration of nebulized *Artemisia afra* extract could thus be a better alternative to the traditionally-used steam inhalation for the treatment of respiratory conditions, provided that other factors (such as convenience, availability of nebulizer) are also considered and dealt with.

In conclusion, inhalation of *Artemisia afra* steam and nebulized *Artemisia afra* extract and luteolin and intravenously-administered luteolin produced improvements in lung function similar to that obtained with known bronchodilators (Svens and Rvriefdt, 2001). *Artemisia afra* extracts containing appreciable amounts of luteolin produced pulmonary effects similar in magnitude to that of luteolin, suggesting that luteolin could be an important contributor to the pulmonary effects of *Artemisia afra*.

Though it was not the objective of this study to determine the mechanism of action of luteolin or *Artemisia afra* effect on the lungs, but it could be speculated that this would include smooth muscle relaxation, and improved surfactant activity (Das et al., 2003). While the above results clearly indicate that *Artemisia afra* improved lung function in a similar way to luteolin, and that luteolin could therefore, be associated
with the pulmonary effects produced by *Artemisia afra*, the mechanism for this effect is yet to be established.
References


Harris, L., 2002. An evaluation of the bronchodilatory properties of *Mentha longifolia* and *Artemisia afra*. Dissertation for a Degree of Master’s in Pharmacy at the University Of The Western Cape, Bellville.


Mjiqiza, S., 2006. Evaluation of the Pulmonary Effects of the Traditionally Prepared *Artemisia afra* Steam Inhalation and Nebulized Aqueous Extract and the Possible Involvement of Flavonoid Luteolin. Dissertation for a M. Pharmacy in Science at the School of Pharmacy, University Of The Western Cape, Bellville.

Muganga, R., 2004. Luteolin Levels in Selected Folkloric Preparations and the Bioavailability of Luteolin from *Artemisia afra* Aqueous Extract in the Vervet Monkey. Dissertation for a Degree of Master’s in Pharmacy at the University Of The Western Cape, Bellville.


http://repository.uwc.ac.za